Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Eric Jonasch MD Advisory Board

Annette Hasenburg Prof., Dr, med Advisory Board

Barbara Burtness MD Advisory Board

See All Experts

featured

Published in Oncology and

Expert Opinion / Interview · March 12, 2018

How I Use PD-1 Inhibitors in RCC

Interview by

Farzanna S Haffizulla MD, FACP, FAMWA

Interview with

Hans Hammers MD, PhD

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Sign in

Not a member?

Join for free

featured

Clinical Validation of a Tissue-Agnostic Genome-Wide Methylome Enrichment Molecular Residual Disease Assay for Head and Neck Malignancies

Ann. Oncol · November 07, 2024
featured

Belantamab Mafodotin, Pomalidomide, and Dexamethasone for Triple Class–Exposed/Refractory Relapsed Multiple Myeloma

Blood Cancer J · November 07, 2024
featured

First-in-Human Study of MTA-Cooperative PRMT5 Inhibitor AMG 193 in Patients With MTAP-Deleted Solid Tumors

Ann. Oncol · November 06, 2024
story of the week

Stereotactic Body Radiotherapy for Localized Prostate Cancer

N. Engl. J. Med · November 06, 2024
story of the week

Perioperative Durvalumab With Neoadjuvant Chemotherapy for Operable Bladder Cancer

N. Engl. J. Med · November 05, 2024

updated
featured

Relationship Between Soluble IL-2 Receptor Levels and Prognosis in DLBCL

Ann Hematol · November 05, 2024
featured

Efficacy of Durvalumab After Chemoradiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

N. Engl. J. Med · November 05, 2024
featured

Pathological Response Following Neoadjuvant Immune Checkpoint Inhibitors in Patients With Hepatocellular Carcinoma

Lancet Oncol · November 04, 2024
featured

Long-Term Outcomes After Perioperative Chemotherapy and Nivolumab for NSCLC

Lancet Oncol · October 31, 2024

updated
featured

Induction Chemotherapy Followed by Standard Chemoradiotherapy vs Standard Chemoradiotherapy Alone for Locally Advanced Cervical Cancer

Lancet · October 31, 2024
story of the week

Hematologic Cancer After Gene Therapy for Cerebral Adrenoleukodystrophy

N. Engl. J. Med · October 30, 2024

Renal Cell Carcinoma

How I Use PD-1 Inhibitors in RCC

Further Reading

Clinical Validation of a Tissue-Agnostic Genome-Wide Methylome Enrichment Molecular Residual Disease Assay for Head and Neck Malignancies

Belantamab Mafodotin, Pomalidomide, and Dexamethasone for Triple Class–Exposed/Refractory Relapsed Multiple Myeloma

First-in-Human Study of MTA-Cooperative PRMT5 Inhibitor AMG 193 in Patients With MTAP-Deleted Solid Tumors

Stereotactic Body Radiotherapy for Localized Prostate Cancer

Perioperative Durvalumab With Neoadjuvant Chemotherapy for Operable Bladder Cancer

Relationship Between Soluble IL-2 Receptor Levels and Prognosis in DLBCL

Efficacy of Durvalumab After Chemoradiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

Pathological Response Following Neoadjuvant Immune Checkpoint Inhibitors in Patients With Hepatocellular Carcinoma

Long-Term Outcomes After Perioperative Chemotherapy and Nivolumab for NSCLC

Induction Chemotherapy Followed by Standard Chemoradiotherapy vs Standard Chemoradiotherapy Alone for Locally Advanced Cervical Cancer

Hematologic Cancer After Gene Therapy for Cerebral Adrenoleukodystrophy

Related Videos